Sponsor or institution
Clinical trials and research at Celcuity Inc
As of November 12, 2026, Find a Trial lists 2 clinical trials run by Celcuity Inc that are recruiting, at sites in 25 countries (most in France (2), Spain (2), United Kingdom (2)). By phase: Phase 3 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 25Countries
All recruiting trials (2)
-
Gedatolisib plus fulvestrant and a CDK4/6 inhibitor for first-line HR-positive, HER2-negative advanced breast cancer
This trial tests whether adding intravenous gedatolisib to fulvestrant plus a CDK4/6 inhibitor (palbociclib or ribociclib) helps people with HR+/HER2- advanced or metastatic breast cancer whose disease progressed during or within 12 months after adjuvant endocrine therapy.
-
Combination of Gedatolisib and Darolutamide for Advanced Prostate Cancer
This study is testing a new combination of two drugs, gedatolisib and darolutamide, to see if they can help men with advanced prostate cancer feel better and improve their treatment outcomes.
Quick answers
How many clinical trials run by Celcuity Inc are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 25 countries. The most sites are in France (2 trials), Spain (2 trials), United Kingdom (2 trials), United States (2 trials), Argentina (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.